Imperial College London
Portrait Picture

Dr Paul Turner

Faculty of Medicine, National Heart & Lung Institute

Reader in Paediatric Allergy & Clinical Immunology
 
 
 
//

Contact

 

+44 (0)20 3312 7754p.turner

 
 
//

Location

 

Children's Clinical Research FacilityCambridge WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gold:2023:10.1016/j.vaccine.2022.11.027,
author = {Gold, MS and Amarasinghe, A and Greenhawt, M and Kelso, JM and Kochhar, S and Yu-Hor, Thong B and Top, KA and Turner, PJ and Worm, M and Law, B},
doi = {10.1016/j.vaccine.2022.11.027},
journal = {Vaccine},
pages = {2605--2614},
title = {Anaphylaxis: Revision of the Brighton collaboration case definition},
url = {http://dx.doi.org/10.1016/j.vaccine.2022.11.027},
volume = {41},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The Brighton Collaboration (BC) has formulated a number of case definitions which have primarily been applied to adverse events of special interest in the context of vaccine safety surveillance. This is a revision of the 2007 BC case definition for anaphylaxis. Recently, the BC definition has been widely used for evaluating reports of suspected anaphylaxis following COVID-19 vaccination. This has led to debate about the performance of the BC definition in comparison with those from the US National Institute of Allergy and Infectious Disease/Food Allergy Anaphylaxis Network (NIAID/FAAN) and the World Allergy Organization (WAO). BC convened an expert working group to revise the case definition based on their usual process of literature review and expert consensus. This manuscript presents the outcome of this process and proposes a revised case definition for anaphylaxis. Major and minor criteria have been re-evaluated with an emphasis on the reporting of observable clinical signs, rather than subjective symptoms, and a clearer approach to the ascertainment of levels of certainty is provided. The BC case definition has also been aligned with other contemporary and international case definitions for anaphylaxis.
AU  - Gold,MS
AU  - Amarasinghe,A
AU  - Greenhawt,M
AU  - Kelso,JM
AU  - Kochhar,S
AU  - Yu-Hor,Thong B
AU  - Top,KA
AU  - Turner,PJ
AU  - Worm,M
AU  - Law,B
DO  - 10.1016/j.vaccine.2022.11.027
EP  - 2614
PY  - 2023///
SN  - 0264-410X
SP  - 2605
TI  - Anaphylaxis: Revision of the Brighton collaboration case definition
T2  - Vaccine
UR  - http://dx.doi.org/10.1016/j.vaccine.2022.11.027
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36435707
UR  - https://www.sciencedirect.com/science/article/pii/S0264410X22014256?via%3Dihub
UR  - http://hdl.handle.net/10044/1/101787
VL  - 41
ER  -
Download